{"schema_version":"secwatch.filing_event.v1","accession":"0001437402-26-000043","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2026-08-06T20:09:56+00:00","discovered_at":"2026-08-06T20:11:31.330108+00:00","generated_at":"2026-08-06T20:13:15.055408+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ardelyx Q2 revenue up 31% to $118.1M; cuts FY2026 IBSRELA guidance to $350-370M","bullets":["Q2 total product revenue $118.1M (+31% YoY); IBSRELA $86.2M (+33%), XPHOZAH $31.9M (+27%).","Net loss $16.7M ($0.07/sh) vs $19.1M ($0.08) prior year; cash $281.8M.","FY2026 IBSRELA guidance revised to $350-370M; XPHOZAH reiterated $110-120M; OPEX below $500M.","Long-term IBSRELA $1B target remains but timing uncertain; XPHOZAH long-term guidance pulled.","Drew $50M from SLR facility; CMS lawsuit dismissed, not appealing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437402-26-000043","json":"https://secwatch.observer/filing/0001437402-26-000043.json","markdown":"https://secwatch.observer/filing/0001437402-26-000043.md","text":"https://secwatch.observer/filing/0001437402-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000143740226000043/0001437402-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000143740226000043/ardx-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:13:15.055408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}